Background; , a member of the ecteinascidin family selected for clinical development, is a tetrahydroisoquinolone alkaloid isolated from the marine ascidian, Ecteinascidia turbinata. This novel compound is a minor groove binding, guanine-specific alkylating agent which also interacts with the microtubule network and blocks cell cycle progression at late S/G2.
Introduction
The family of ecteinascidins (ETS), DNA-active tetrahydroisoquinolone alkaloids isolated from the marine ascidian Ecteinascidia turbinata, has been associated with multiple anticancer activities. Ecteinascidins have been reported to induce significant antitumor effects in mice bearing P388 lymphoma, B16 melanoma, M5076 ovarian sarcoma, Lewis and LX-1 human lung carcinoma, and MX-1 mammary tumor xenografts [1] . Ecteinascidins have been shown to bind strongly with DNA, but without a formation of permanent covalent adducts [1] .
Ecteinascidin-743 (ET-743), a novel member of the ET family, is a guanine-specific, minor groove binding agent. ET-743 was selected for clinical development based on antitumor activity comparable to that of a structurally related ecteinascidin, ET-729, which demonstrated exceedingly potent activity in vivo [1] , and on the greater abundance of ET-743 relative to other ecteinascidins in the tunicate. Recently the solution structure of ET-743-DNA adduct has been reported [2] . This study revealed sequence specificity of ET-743 for DNA duplexes containing both GGC and AGC as putative alkylation sites. The implications of the study are that while units A and B of ET-743 bind to DNA duplexes, unit C might act as a 'fishing hook' for interaction with transcription factors.
The antitumor activity of ET-743 may also be a result of interaction with the microtubule network of the cell. ET-743 has been shown to disorganize microtubule bundles but does not appear to interact directly with tubulin [3, 4] . ET-743 was also found to block progression at late S/G2 phases of the cell cycle [3, 4] .
Initial in vitro studies of showed that the drug was active at nanomolar concentrations against solid tumor cell lines including non-small-cell lung and melanoma [5] . Subsequent evaluation of ET-743 against the NCI human in vitro cell line panel demonstrated antiproliferative effects of ET-743 at 1 pM to 10 nM in melanoma, non-small-cell lung, ovarian, renal, prostate, and breast cancer cell lines [5, 6] .
In vitro testing against human tumor cell lines revealed that ET-743 was most active in a continuous exposure against non-small-cell lung, colon, and breast cancer cell lines [7, 8] . ET-743 had at least additive activity with vinorelbine or paclitaxel against the CALU-3 lung adenocarcinoma cell line and with paclitaxel against the MCF-7 breast adenocarcinoma cell line [7, 8] .
In the present study we evaluated the activity of ET-743 against fresh human tumor specimens isolated directly from patients using a clonogenic assay system. Through the initial work of Hamburger and Salmon, it is now possible to culture human tumors using a twolayer soft agar system [9, 10] . This human tumor cloning system was initially utilized to select the most appropriate anticancer agent for an individual patient's tumor [11] , From several encouraging in vitro/in vivo correlations, it became obvious that the cloning system might also be utilized to screen for antitumor activity of new compounds [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . In this report we describe use of the cloning system to determine the concentration and exposure of ET-743 which must be achieved to see the antitumor activity of this compound and to determine the spectrum of activity against human tumor colonyforming units. The results suggest that a long-term exposure of human tumors may improve the antitumor activity of ET-743. The in vitro results on ET-743 tumor specificity may also help pinpoint the tumor types that should receive particular attention in phase II clinical trials.
Materials and methods

ET-743
Purified ET-743 ( Figure 1 ) was provided by PharmaMar (Madrid, Spain) and diluted to create concentrated stocks. One-half milliliter (0.5 ml) aliquots of each stock were labeled and stored at -70 °C. Aliquots were thawed for each new tumor sample tested. The drug, diluted in normal saline, is stable at room temperature for up to 24 hours [6].
Collection of tumor cells
After obtaining informed consent in accordance with federal and institutional guidelines, malignant effusions, ascites and bone marrow aspirates containing tumor cells, as well as solid tumor specimens, were collected from patients undergoing procedures done as part of their diagnostic workup or as part of treatment for their disease. No samples were obtained solely for research purposes. Figure 1 . Chemical structure of ET-743. serum, 50 U/ml penicillin, and 50 ug/ml streptomycin (all Gibco, Grand Island, NY). Within four hours, these solid tumors were mechanically disassociated with scissors, forced through No. 100 stainless steel mesh, sieves (Sigma) through 25 gauge needles, and centrifuged at 1000 rpm for seven minutes. Harvested cells are then washed with McCoys medium 5A, plus 20 mM Hepes buffer (Sigma), 10% fetal calf serum (Tissue Culture Biologicals, Tulare, CA), 2 mM sodium pyruvate, 50 U/ml penicillin, and 50 ug/ml streptomycin (Gibco). Ascitic, pleural, pericardial fluids and bone marrows were obtained by standard techniques and placed in sterile containers. Ten U/ml preservative-free heparin (Sigma) was added immediately after collection of fluid or bone marrow to prevent coagulation. After centrifugation at 1000 rpm for seven minutes, the cells were harvested and washed as above. The viability of cell suspensions was determined on a hemacytometer with trypan blue.
Cell cultures
Cells to be cloned were suspended in 0.3% agar (Difco, Detroit, Ml) in double enriched CMRL 1066, supplemented with 50 U/ml penicillin, 50 ug/ml streptomycin, 0.3 mM ascorbic acid, 2 mM GlutaMAX-1, 0.6 mg/ml asparagine (all Gibco), 15% heat inactivated horse serum (Sigma), 2 U/ml insulin (Sigma), and 2% heat inactivated fetal calf serum (Tissue Culture Biologicals). For the continuous exposure ET-743 was added to the above mixture. Cells were plated at a density of 5 x 10 5 in 35 mm Petri dishes (Corning, Corning, NY) in a top layer of agar over a base layer of 0.3% agar, enriched McCoy's 5A supplemented with 5% heat inactivated horse serum, 10% heat inactivated fetal calf serum, 2 mM sodium pyruvate, 0.042 ug/ml L-Serine (Gibco), 2 mM GlutaMAX-1, 250 U/ml penicillin, and 50 ug/ml streptomycin, to prevent growth of fibroblasts. Three plates were prepared for each data point. For the one hour exposure studies, the cells were incubated for one hour with ET-743, washed to simulate the disappearance of the drug from the body, then plated in the top layer of agar just as was done for the continuous exposure studies.
Quality control
To assure the presence of an excellent single cell suspension on the day of plating, positive and untreated controls were used in addition to the drug treated cells. For each tumor tissue sample tested, three positive control plates were set up to contain the cell poison orthosodium vanadate at 200 ug/ml. This positive control should destroy all clonogenic cells. Three untreated control plates were also set up on day 0. The plates were placed in a 37 = C incubator, and were removed on day 14 for counting of the number of colonies in each plate. If there was no effect on colony formation, then the single cell suspension on day 0 was poor (since orthosodium vanadate does not affect clumps), the tumor sample test was considered non-evaluable, and excluded from the results.
Definition of an in vitro response and statistical analysis
A test is denned as an experiment, performed on a unique tumor tissue sample, that contains untreated control, positive control, and three specified compound concentration levels. An evaluable test is one having an average of 20 or more colonies present on day 14 in the untreated control plates and <30% survival in the positive control (orthosodium vanadate) plates when compared to untreated control plates. The number of colonies (defined at > 50 cells) formed in the three compound-treated plates were compared to the number of colonies formed in the three control plates, and the percent colonies surviving at that concentration of compound was calculated.
Pairwise comparisons of the percent colonies surviving at different concentrations or different exposures were performed by paired /-tests. Pairwise comparisons of in vitro response rates were performed by McNemar's test for paired proportions.
Results
Human tumor cloning assay: evaluable specimens
The effects of ET-743 at concentrations ranging from 0.1 nM to 1 |iM were evaluated against human tumor colony-forming units at one-hour or 14-day continuous exposure in a total of 172 specimens taken directly from patients. ET-743 antiproliferative activity was studied at a one-hour exposure in a total of 45 tumors from which 25 (56%) were evaluable and at a continuous exposure in 172 patients from which 92 (53%) were evaluable. As shown in Table lb , the most common tumor types were breast (n = 15), ovary (n = 21), and non-small-cell lung cancers (n = 14).
In vitro responses to one-hour exposure
ET-743 antiproliferative activity was studied at a onehour exposure in a total of 45 tumors from which 25 (56%) were evaluable. As shown in Table la , at concentrations of 0.1 nM, 1 nM, 10 nM, 100 nM and 1 uM, in vitro responses (denned as inhibition of ^ 50% of human tumor colony forming units) were observed in 0% (0/17), 6% (1/17), 16% (4/25), 13% (1/8), and 25% (2/8) of specimens, respectively. McNemar's test for paired proportions were P -0.083 for 10 nM vs. 1 nM; P = 0.317 for 100 nM vs. 10 nM; P = 0.317 for 1 uM vs. 100 nM, and was not significant for the two lowest concentrations. Since there was little activity of ET-743 in these tumors, testing at one-hour exposure was discontinued after 25 evaluable specimens.
In vitro responses to continuous exposure ET-743 antiproliferative activity was studied at a continuous exposure in 172 tumors from which 92 (53%) were evaluable. Under these conditions, ET-743 at 0.1 nM, 1 nM, 10 nM, 100 nM and 1 uM, inhibited, respectively, 0% (0/16), 13% (2/16), 49% (44/90), 62% (47/76), and 77% (58/75) of tumor specimens (Table lb) .
Pairwise comparisons of in vitro response rates at different concentrations performed by McNemar's test for paired proportions indicated that there was a significant dose-response relationship. With the exception of the two lowest concentrations, each dose produced significantly more responses than the next lowest concentration (P -0.025 for 10 nM vs. 1 nM; P = 0.033 for 100 nM vs. 10 nM; P = 0.001 for 1 uM vs. 100 nM).
Tumor specificity
ET-743 inhibited colony-forming units in a broad spectrum of patients' tumors. Tumor-specific responses were observed in a continuous exposure to ET-743 (Table lb) . A clear concentration-dependent relationship was observed for most tumor types. For example, ET-743 inhibited 40% (6/15), 79% (11/14), and 100% (14/14) of breast tumors at concentrations 10 nM, 100 nM, and 1 uM, respectively. Similar relationships were seen for ovary (45%, 58%, 67%) and non-small-cell lung (50%, 69%, 85%).
Comparison of ET-743 with other alkylating agents
To compare the relative sensitivity of the tumors to ET-743 (all evaluations done at an optimal 10 nM ET-743, continuous exposure) and other alkylating agents, headto-head analyses have been performed (Table 2 ). The selected concentrations of the alkylating agents were based on the drug concentrations achievable in patients, and usually in the range of 0.1-1 x peak plasma levels. A comparison of ET-743 with 4-hydroxycyclophosphamide (CTX) at 3 ug/ml showed that six tumors (one breast, five ovarian) were sensitive to both agents, six (including three breast tumors) were sensitive to ET-743 and resistant to CTX, one breast tumor was sensitive only to CTX, and 12 tumors (including four breast and six ovarian) were resistant to both drugs.
With adriamycin at 0.04 ug/ml, 17 specimens were sensitive to ET-743 and resistant to adriamycin (including three breast and six ovarian), and 12 specimens were resistant to both agents.
When ET-743 was compared with cisplatin at 0.2 ug/ml, five tumors (including lung and sarcoma) were sensitive to both agents, and 18 tumors (including two breast, four non-small-cell lung, four melanoma, six Abbreviations: S/S -sensitive to both ET-743 and the agent; S/Rsensitive to ET-743 but resistant to the agent; R/S -resistant to ET-743 but sensitive to the agent; R/R -resistant to both ET-743 and the agent. Sensitive defined as < 50% survival at the given concentration.
ovarian) were sensitive to ET-743, but resistant to cisplatin. No tumors resistant to ET-743 responded to cisplatin, and 28 tumors (including five breast, two kidney, three non-small-cell lung, two melanoma, eight ovarian, and one sarcoma) were resistant to both drugs. Four ovarian tumor specimens were sensitive to ET-743 and resistant to N-hydroxyhexamethylmelamine (HMM) at 1 ug/ml, one tumor was more sensitive to HMM and resistant to ET-734; and four tumors (including three ovarian) were resistant to ET-743, but sensitive to HMM.
In a comparison between ET-743 and BCNU at 0.1 ug/ml, four melanoma specimens were sensitive to ET-743 and resistant to BCNU, and one melanoma specimen was resistant to both drugs.
Comparison of ET-743 with other tubulin-interactive agents
An analysis of the relative sensitivity of the tumors to ET-743 (all evaluations done at 10 nM ET-743, continuous exposure) and other tubulin-interactive agents has been also done in head-to-head comparisons ( Table 2 ). The concentrations of the tubulin-interactive agents selected for the head-to-head comparisons were related to the peak plasma levels achievable in patients.
In comparison of ET-743 with paclitaxel at 0.25 ug/ml, only one non-small-cell lung and one breast tumor were sensitive to both agents and 17 tumors (three breast, five non-small-cell lung, two other, seven ovarian) were resistant to paclitaxel and ET-743. Interestingly, fourteen tumors (including three breast, two melanoma, seven ovarian) were sensitive to ET-743 but resistant to paclitaxel, while only one ovarian tumor was sensitive to paclitaxel but resistant to ET-743. The patterns of tumor responsiveness seen with paclitaxel at 2.5 and 10 ug/ml concentrations (achievable in patients) were qualitatively similar. The extent of cross-resistance of ET-743 and paclitaxel at 100 ug/ml was decreased at this suprapharmalogical concentration (data not shown).
When ET-743 was compared with vinblastine at 0.05 ug/ml, there were no tumors sensitive to both agents, three tumors (one breast, one melanoma, one other) were sensitive to ET-743 and resistant to vinblastine, one breast tumor was sensitive to vinblastine and resistant to ET-743, and three tumors (breast, melanoma, sarcoma) were resistant to both agents.
Discussion
In this study we evaluated the effect of ET-743 at two different exposures (one-hour and continuous) against a broad range of primary human tumors taken directly from patients. Our data suggest that the duration of exposure significantly affects ET-743 toxicity against human tumor colony-forming units. Previous in vitro studies using human cancer cell lines have shown that the long-term exposure produced a higher extent of inhibition than a one hour exposure [6] . The recent data further support that observation and suggest that the continuous mode of administration of the drug may be preferred over a bolus injection in a clinical situation.
The effects of the schedule on the antitumor activity of ET-743 strongly suggest that the continuous exposure is significantly more effective (P = 0.073 at 100 nM and P = 0.0156 at 1 uM). Not all minor groove binders follow the same schedule clinically. For example, the schedule of clinical administration of other minor groove binders vary from a short (1-5 min) infusion of daunorubicin [26] to a long-term for plicamycin, which is administered daily for eight to 10 days [27] . However, our results comparing effects of one-hour versus continuous exposure to adriamycin and cisplatin on the inhibition of human tumor colony-forming units indicate that there is no significant difference between the two schedules for adriamycin (P -0.2045) and cisplatin (P = 0.5649). Since the cytotoxic action of ET-743 is quite different than that of other minor groove binders, it is likely to have additional cellular targets.
The tumor-specific effects from our study indicate that breast, lung, melanoma, and ovarian cancers may be interesting targets for the future clinical trials. The observation of the tumor specificity (which may be emerging from the inhibition of colony formation that was achieved at lower concentrations of ET-743) is in line with the earlier report of ET-743's effect on human tumor cell lines in vitro [3] . Interestingly, the same tumor types (e.g., lung, melanoma, and breast) appeared to be good targets for other ecteinascidins in vivo [1, 4] . ET-743 was evaluated against breast cancer xenografts using the MX-1 advanced model, in which the therapy started at day 9 after implant. Optimal doses produced up to 90% complete remission (CR) at day 23, with up to 40% of the treated animals in CR on day 58 of the follow-up period [4, 28] . These results obtained in the human metastatic breast cancer model encouraged a study using HOC 18 human ovarian tumor xenograft partially resistant to cisplatin. In this/« vivo study, which mimicked advanced disease model, the activity of ET-743 was confirmed in nude mice bearing high tumor burdens [29] . ET-743 was more active than ifosfamide, DTIC, and cisplatin in the following human cell lines: melanoma (MEXF989), non-small-cell lung cancer (LXFL529), and ovarian carcinoma (HOC-22) [30] . Long-lasting complete remissions in these cell lines occurred at the respective MTD's of 200 and 100 ug/kg administered i.v. on q4d x 3 (days 0, 4, 8) or qd x 3 x 2 (days 0-2, 13-15) [31] . Additional in vivo studies performed in the human tumor cell lines from non-small-cell lung cancer (LXAF629), melanoma (MEFX514), and ovarian carcinoma (HOC18), were resistant to ifosfamide, DTIC and cisplatin, respectively. These results suggests that ET-743 lacks complete cross-resistance with the above compounds. When ET-743 was administered i.v. to tumorbearing mice, inhibition of G101 metastatic breast tumor growth was observed with a single 250 ug/kg dose [6] .
Considering possible multiple cellular targets for ET-743, a more extensive head-to-head comparison of ET-743 with other minor groove binding agents and/ or alkylators (cisplatin, 4-hydroxycyclophosphamide, N-hydroxyhexamethylmelamine, adriamycin), as well with other tubulin-interactive agents (vinblastine, paclitaxel) might be of interest. In the present study, such evaluations have been done on a limited basis. Our data indicate that ET-743 may indeed show some antitumor activity in patient tumors resistant to some of the above agents. In particular, incomplete cross-resistance between ET-743 and cisplatin and paclitaxel in ovarian tumors opens the possibility that ET-743 may inhibit the growth of some tumors resistant to other drugs. In the future, work addressing the patterns of cross-resistance and cross-sensitivity with well established agents should yield clinically relevant data.
Further exploration of the ET-743 recognition targets in DNA sequences may be important. In particular, the specificity of ET-743 for G-rich sequences is intriguing. With minor groove G-rich sequences as a target, an important area of future research must focus on the interactions with transcription factors and histones. Whether the DNA sequence specificity is limited to the GGC/AGC putative alkylation sites or can also include the G-rich telomeric repeats is not known at present. Recent experimental evidence suggests that ET-743 may have an affinity to a telomere-like DNA sequence. Sakai et al. [1] presented a generic model of the ectenaiscidin-DNA adduct to the heptamer d(TTGGGAA). In this energy-minimized model, the middle G is the primary target for alkylation by ET-743. Interestingly, that DNA sequence alkylated by ET-743 is similar to the human (TTAGGG)n telomeric repeat [32] .
Telomerase activity is elevated in a vast majority of cancers, yet is present in only a few types of normal cells, such as stem and germ cells [33, 34] , Therefore, inhibition of telomerase, which can be achieved either as a direct inhibition of the enzyme, or an interference with the substrate (telomere), might represent an attractive, and a very selective anticancer tool. Disruption of the telomere structure, leading to inhibition of telomerase activity has been proposed as a possible antitumor mechanism [35] . Recently, telomere-interactive agents have been reported to inhibit telomerase activity in vitro [36] [37] [38] . Examination whether ET-743 exhibits telomerase inhibitory activity in vitro will certainly be a worthwhile effort.
Although the mode of ET-743 action still remains elusive, we think that the results of these in vitro studies might facilitate the clinical development of ET-743 (and its novel analogs based on a rational drug design) by defining the optimum dosing schedule, targeting specific tumor types and determining appropriate combination regimens. Our current data provide us with the information on the schedule dependence of the in vitro antitumor activity and identification of the tumor types that are sensitive to low concentrations of ET-743. Our data correlate with the plasma levels of the drug in mice at the maximum tolerated doses (MTD) of 600 ug/m 2 with the in vitro concentrations (10 nM and 100 nM). The 10 nM concentration can be achieved within 'A MTD, while 100 nM level can be reached at the MTD levels. That MTD remains the dose level that induces longlasting complete responses in human tumor xenografts in nude mice.
In conclusion, this study shows that the schedule of administration is an important parameter in ET-743 cytotoxicity. Concentrations above 10 nM as continuous 14-day exposure were associated with high in vitro response rates. The drug is currently in clinical phase I evaluation including the evaluation of a continuous infusion schedule. As the responses to ET-743 can be achieved in human tumors at physiologically relevant concentrations of ET-743, the in vitro activity of suggests that the drug may deserve future clinical trials in patients with ovarian, breast, and non-small-cell lung carcinomas.
